丸美生物旗下拥有"丸美"与"恋火"两大核心品牌。弗若斯特沙利文报告显示，以2024年零售额计，丸美 品牌已连续四年位列中国国内眼部护理品牌第一，而恋火品牌则在中国国货底妆品牌中排名第三。 此次发行将助力公司把握中国抗衰护肤品市场的增长机遇。弗若斯特沙利文报告指出，抗衰护肤品是中 国护肤品行业中增速最快的细分领域。通过本次募资，公司将持续投入以重组胶原蛋白为代表的核心技 术研发，进一步巩固其技术壁垒。截至2025年9月30日，公司已在全球申请专利651项，获得授权发明专 利265项，研发实力位居国内美妆企业前列。此举将增强公司在激烈市场竞争中的差异化优势，巩固其 行业领先地位。 针对核心原料，公司已建立覆盖从基础研究到应用的闭环价值链。截至2025年9月30日，已开发出重组 双胶原蛋白、SPGβ－葡聚糖、超分子木棉花提取物、超分子弹性蛋白等80余款自有成分，其中30余款 实现规模化生产。其自有的生产基地能够开展用于重组胶原生产的高密度发酵与纯化工艺，有效衔接基 础研究与产业化生产。 公司强调，此次H股发行不会导致公司控制权发生变更，孙怀庆博士与王晓蒲仍为公司实际控制人。公 司拟通过本次发行募集资金，在扣除相关发 ...

大会名称 | 2026第四届合成生物学产业博览会（SBC2026） 大会主题 | 合成未来趋势·智造无限可能 大会时间 | 2026年4月17-18日 大会地点 | 江苏南京扬子江国际会议中心 主办单位 | 佰傲谷BioValley、生物经纬、山东大学、华东理工大学、山东大学微生物技术国家重点实验 室 支持单位 | 中国微生物学会、 中国微生物学会生化过程模型化与控制专业委员会、 华东理工大学国家 生化工程技术研究中心(上海)、北京软物质科学与工程高精尖中心、上海市微生物学会、南京生物工程 学会、华东师范大学医学合成生物学研究中心、工业生物催化教育部重点实验室 合成未来趋势·智能无限可能 扫码提前解锁观摩席位 合成生物学作为21世纪生命科学领域的颠覆性力量与全新生产力，正以DBTL循环"编程"生命，为人类 在健康、能源、环境等领域的重大挑战提供全新的解决方案，引领我们步入一个能够按需设计、改造乃 至创造生命的"生物世纪"。在我国"十五五"规划中，合成生物学与生物制造被提升至与量子科技并列的 战略高度，作为未来产业进行持续培育，目标形成万亿级产业规模。 SBC2026第四届合成生物学产业博览会 将实现科技深度与 ...

"AI正对传统农业生产方式、生产关系和治理体系带来深层变革，成为实现农业现代化、保障国家粮食 安全和推动乡村振兴的关键技术支撑。"南京农业大学党委常委、副校长丁艳锋介绍，近年来，南京农 业大学在14个学科进入ESI全球前百分之一、3个学科进入前千分之一，植物学与动物学、农业科学跻身 前万分之一的坚实基础上，进一步前瞻布局成立前沿交叉研究院，围绕农业人工智能、植物表型组学、 农业与人类健康、合成生物学等新型方向大力推动学科交叉，一批前沿成果不断涌现，为科技赋能农业 发展注入新动能。(经济日报记者蒋波) 会上，"fomo4wheat作物表型大模型""AI+遥感驱动的作物数字孪生系统""作物动态智能设计育种大模 型""大豆智慧育种平台""'药问'农药科学家智能体"等五款农业AI领域成果正式推出。fomo4wheat作物表 型大模型构建起小麦视觉感知AI底座，遥感驱动作物数字孪生系统实现"感知-建模-决策"全链路贯通， 作物动态智能设计育种大模型将育种周期缩短至少50%，大豆智慧育种平台打造全球领先的大豆育 种"超级大脑"，"药问"农药科学家智能体则将农药研发周期从十年压缩至一年，整体构建起从基础研究 到产业应用的完 ...

Core Viewpoint - Chuaning Bio, a leading company in the domestic bio-fermentation technology sector, has extended the lock-up period for its pre-IPO shares held by its controlling shareholder, Sichuan Kelun Pharmaceutical, until December 27, 2026, to enhance investor confidence and stabilize the capital market [1] Group 1: Shareholder Commitment - The lock-up extension involves approximately 1.61 billion shares, accounting for 72.19% of the company's total share capital [1] - This commitment reflects the controlling shareholder's confidence in the company's future development and intrinsic value [1] Group 2: Production and Market Outlook - Chuaning Bio reported that its three major intermediates are operating at full capacity, although the overall shipment volume has decreased by about 8% year-on-year [2] - The company anticipates a potential recovery in market demand for penicillin products, with prices currently at historical lows, and expects a positive trend as the traditional peak season approaches [2] - The company has initiated a collaboration with Shanghai Jincheng Technology to leverage AI in enhancing production efficiency in bio-fermentation [2] Group 3: AI and Product Development - The AI virtual engineer has shown an average production increase of 3%-5% compared to the control group and can predict fermentation trends in real-time [3] - Revenue from synthetic biology products reached 48.8 million yuan in the first three quarters of 2025, with improved order conditions compared to the previous year [3] - The company expects significant revenue growth in synthetic biology products as production capacity increases and market expansion continues [3] Group 4: Management's Strategic Focus - The management plans to deepen technological innovation, optimize industrial layout, and enhance operational quality to reward shareholders' trust and support [4] - Chuaning Bio aims to become a significant innovative force in the global biotechnology sector, creating sustainable value for shareholders [4]

中证报中证网讯（王珞）近日，广东丸美生物（603983）技术股份有限公司（以下简称"丸美生物"）发 布H股申请资料，公司拟通过本次发行募集资金，在扣除相关发行费用后，全部用于强化公司核心战 略，包括加强全渠道销售体系、提升品牌价值与孵化新品牌、增强研发能力、优化供应链以及补充公司 营运资金，旨在全面提升公司的综合竞争力。 深耕抗衰二十余年 胶原蛋白领军品牌之一 资料显示，丸美生物以合成生物学技术驱动，深耕抗衰护肤品行业二十余年，不断通过专注于研发及以 重组胶原蛋白为代表的核心技术突破，将前沿科技创新应用到具有抗皱、紧致和修护等功效的护肤产品 中。 基于弗若斯特沙利文报告，以2024年零售额计，丸美生物是重组胶原蛋白护肤品细分领域的中国第三大 美妆企业。 自企业创立以来，丸美生物坚持产品的成分及功效研究，已建立一个一体化研发平台。通过涵盖合成生 物学、蛋白工程、绿色化学、天然植物提取及生物发酵的系统研发，持续推出支持业务增长的新成分与 产品。 针对核心原料，公司已建立覆盖从基础研究到应用的闭环价值链。截至2025年9月30日，已开发出重组 双胶原蛋白、SPGβ－葡聚糖、超分子木棉花提取物、超分子弹性蛋白等80余 ...

Group 1 - The core viewpoint of the news is that Baoyi Pharmaceutical-B (02589) has successfully listed on the Hong Kong Stock Exchange, with a significant first-day increase of 138.82%, leading to a market capitalization exceeding HKD 20 billion [1] - As of the latest update, Baoyi Pharmaceutical-B's stock price rose by 3.79% to HKD 68.45, with a trading volume of HKD 18.38 million [1] - The company focuses strategically on four key areas: large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproduction, and recombinant biopharmaceuticals [1] Group 2 - Baoyi Pharmaceutical has developed a unique "pyramid" pipeline structure, which is supported by a combination of scenario-driven strategic choices, technological barriers in synthetic biology, and industrialization advantages of total cost leadership [2] - The base of the "pyramid" pipeline consists of products with short clinical cycles, low costs, and high market demand certainty, such as the approved SJ02 and the NDA-submitted KJ017 [2] - This product focus allows Baoyi Pharmaceutical to quickly generate stable sales and cash flow, providing the company with self-sustaining capabilities and alleviating the common financing anxiety faced by 18A enterprises [2]

Group 1 - The core viewpoint of the news is that Baoji Pharmaceutical-B has successfully listed on the Hong Kong Stock Exchange, with a significant first-day increase of 138.82%, leading to a market capitalization exceeding 20 billion HKD [1] - As of the latest update, Baoji Pharmaceutical-B's stock price rose by 3.79% to 68.45 HKD, with a trading volume of 18.38 million HKD [1] - The company focuses strategically on four key areas: large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproduction, and recombinant biopharmaceuticals [1] Group 2 - Baoji Pharmaceutical-B has developed a unique "pyramid" pipeline structure, which is supported by a "scene-driven" strategic choice, synthetic biology technological barriers, and a "total cost leadership" industrial advantage [2] - The base of the "pyramid" pipeline consists of products with short clinical cycles, low costs, and high market demand certainty, such as the already approved SJ02 and the NDA-submitted KJ017 [2] - This product focus allows the company to quickly generate stable sales and cash flow, providing a "self-sustaining" capability that alleviates the common "financing anxiety" faced by 18A companies [2]

值得一提的是，截至2024年年报，川宁生物净利润已从上市前的约1.1亿增长至14亿元。同时，截至 2025年6月，川宁生物也完成了上市第三年的第三次分红，累计分红总金额累计达13亿元，已经完全覆 盖上市的募集资金金额11亿元，用实际行动践行了"质量回报双提升"行动理念。（秦声） （文章来源：证券时报网） 资料显示，资料显示，川宁生物属于医药制造业，地处霍尔果斯经济开发区是共建"一带一路"的核心区 域，公司始终坚持发展"生物发酵"与"合成生物学"双轮驱动战略，目前主要从事生物发酵技术和合成生 物学产品的研发和产业化。主要产品为硫氰酸红霉素、6-APA、青霉素G钾盐、头孢类（中间体）、熊 去氧胆酸、红没药醇等。其中硫氰酸红霉素、头孢类（中间体）、青霉素类中间体产量均位居全球前 列，熊去氧胆酸已于2024年7月9日收到国家药品监督管理局对公司化学原料药熊去氧胆酸的化学原料药 上市申请批准通知书，获准在国内合法生产与销售。 此外，川宁生物合成生物学目前的量产产品有红没药醇、五羟基色氨酸、麦角硫因、角鲨烷、肌醇等。 其中，明星产品麦角硫因原料已上市，目前主要应用于化妆品原料、保健品原料等领域，并正在积极拓 展市场。 公 ...

Core Insights - The article discusses the evolution of Google and its approach to AI, highlighting both past mistakes and future opportunities in the context of education and technology [3][10][12]. Group 1: Google's AI Strategy - Google initially missed opportunities in AI commercialization due to hesitance in promoting chatbots, fearing they would produce nonsensical outputs [3][15]. - The company's competitive edge in AI stems from long-term investments in foundational technologies, such as AI-specific chips (TPUs) and large-scale data centers [4][16]. - Future breakthroughs in AI are expected to rely more on algorithmic advancements rather than merely scaling data and computational power [5][29]. Group 2: Education and Career Guidance - Students should view AI as a tool to enhance their capabilities rather than a reason to abandon traditional fields like computer science [7][18]. - The future of universities may shift away from geographical constraints, emphasizing remote learning and collaboration [20][21]. - The path from academia to industry may need reevaluation as the timeline for turning ideas into commercial products shortens [22][23]. Group 3: Research and Innovation - While industry leads many innovations, academic research remains crucial for long-term exploratory projects that require extensive timeframes [24][25]. - Emerging technologies, particularly in materials science, are seen as underappreciated areas with significant potential for impact [32][34].

继眉间纹后又一适应症取得关键进展。 本文为IPO早知道原创 作者｜罗宾 微信公众号｜ipozaozhidao 据 IPO 早知道消息， 12 月 11 日，君合盟生物制药（杭州）有限公司 （ 下称 "君合盟生物" ） 宣布，其自主研发并由其全资子公司君合盟生物制药（通化）有限公司生产和申请的注射用重组 A 型肉毒毒素用于治疗成人脑卒中后上肢痉挛取得关键进展，其临床 III 期试验获国家 药监局 批准。 该 III 期 临床试验由复旦大学附属华山医院李放教授和上海市养志康复医院（即上海市阳光康复中 心）靳令经教授联合牵头，已正式启动，并完成重组 A 型肉毒毒素治疗该适应症临床 III 期试验全 球首例患者入组，为该治疗领域的发展带来新的突破。 本文由公众号IPO早知道（ID：ipozaozhidao）原创撰写，如需转载请联系C叔↓↓↓ 此前，注射用重组 A 型肉毒毒素用于成人中、重度眉间纹适应症的 III 期临床试验已在北京大学第 一医院正式启动并完成首例入组。 君合盟生物是一家专注合成生物学技术的创新型企业，致力于推进创新重组蛋白药物在内分泌、神经 治疗和新一代生物医用材料等方面的应用，旨在为全球患者提供突破 ...